These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28154202)

  • 21. Mesalazine improves replication fidelity in cultured colorectal cells.
    Gasche C; Goel A; Natarajan L; Boland CR
    Cancer Res; 2005 May; 65(10):3993-7. PubMed ID: 15899787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer.
    Saleh AJ; Soltani BM; Dokanehiifard S; Medlej A; Tavalaei M; Mowla SJ
    Tumour Biol; 2016 Oct; 37(10):14089-14101. PubMed ID: 27511117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
    Paleari L; Puntoni M; Clavarezza M; DeCensi M; Cuzick J; DeCensi A
    Clin Oncol (R Coll Radiol); 2016 May; 28(5):317-26. PubMed ID: 26712086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Aspirin and colorectal cancer].
    Grancher A; Michel P; Di Fiore F; Sefrioui D
    Bull Cancer; 2018 Feb; 105(2):171-180. PubMed ID: 29153543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
    Li WM; Hu TT; Zhou LL; Feng YM; Wang YY; Fang J
    BMC Cancer; 2016 Jul; 16():454. PubMed ID: 27405731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
    Ross RL; McPherson HR; Kettlewell L; Shnyder SD; Hurst CD; Alder O; Knowles MA
    BMC Cancer; 2016 Jul; 16():553. PubMed ID: 27465249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
    Ghodsinia AA; Lego JMT; Garcia RL
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
    Wang Q; Shi YL; Zhou K; Wang LL; Yan ZX; Liu YL; Xu LL; Zhao SW; Chu HL; Shi TT; Ma QH; Bi J
    Cell Death Dis; 2018 Jul; 9(7):739. PubMed ID: 29970892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
    Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
    Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer.
    Toden S; Okugawa Y; Buhrmann C; Nattamai D; Anguiano E; Baldwin N; Shakibaei M; Boland CR; Goel A
    Cancer Prev Res (Phila); 2015 May; 8(5):431-43. PubMed ID: 25712055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
    Samuels Y; Diaz LA; Schmidt-Kittler O; Cummins JM; Delong L; Cheong I; Rago C; Huso DL; Lengauer C; Kinzler KW; Vogelstein B; Velculescu VE
    Cancer Cell; 2005 Jun; 7(6):561-73. PubMed ID: 15950905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
    Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
    Abubaker J; Bavi P; Al-Harbi S; Ibrahim M; Siraj AK; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    Oncogene; 2008 Jun; 27(25):3539-45. PubMed ID: 18193083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.